Stock Events

Stock Events

Vaxcyte 

$63.25
39
+$3.45+5.78% 18:58 Today

Statistics

Day High
63.32
Day Low
61.78
52W High
63.25
52W Low
30.25
Volume
23,744
Avg. Volume
-
Mkt Cap
9.41B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.3
-1.87
-1.45
-1.02
Expected EPS
-2.118889
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-766.63MNet Income

Analyst Ratings

89.00Average Price Target
The highest estimate is 89.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PCVX. It's not an investment recommendation.
Microsoft
7
MSFT
AMD
7
AMD
Tesla
6
TSLA
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap152.69B
Pfizer, through its acquisition of Wyeth, is a direct competitor in the pneumococcal vaccine market, competing with Vaxcyte's pneumococcal vaccine candidates.
Merck
MRK
Mkt Cap335.14B
Merck & Co. produces Pneumovax 23, a pneumococcal vaccine that competes with Vaxcyte's vaccine candidates targeting similar diseases.
GSK
GSK
Mkt Cap99.18B
GlaxoSmithKline competes in the pneumococcal vaccine space with its Synflorix and other pneumococcal vaccine developments, making it a competitor to Vaxcyte.
Sanofi
SNY
Mkt Cap104.76B
Sanofi, through its vaccines division Sanofi Pasteur, is involved in developing vaccines that could compete with Vaxcyte's pneumococcal vaccine candidates.
Novavax
NVAX
Mkt Cap1.33B
Novavax is involved in the development of vaccines for infectious diseases, which could put it in competition with Vaxcyte, especially if it enters the pneumococcal disease space.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech, known for its mRNA technology, could potentially develop vaccines that compete with Vaxcyte's pneumococcal vaccine candidates.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its Janssen Pharmaceuticals division, works on vaccines that could compete with Vaxcyte's offerings in the infectious disease arena.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a broad portfolio of vaccines and could become a competitor if it decides to expand into pneumococcal or similar vaccines.

About

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Show more...
CEO
Grant E. Pickering
Employees
507
Country
United States
ISIN
US92243G1085
WKN
000A2P6R6

Listings

MI
IT
1PCVX.MI
MU
DE
5VA.MU
XETRA
DE
5VA.XETRA
STU
DE
5VA.STU

0 Comments

Share your thoughts

FAQ

What is Vaxcyte stock price today?▼
The current price of PCVX is $63.25 USD — it has increased by +5.78% in the past 24 hours. Watch Vaxcyte stock price performance more closely on the chart.
What is Vaxcyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vaxcyte stocks are traded under the ticker PCVX.
Is Vaxcyte stock price growing?▼
PCVX stock has risen by +6.03% compared to the previous week, the month change is a +12.54% rise, over the last year Vaxcyte has showed a +99.32% increase.
What is Vaxcyte market cap?▼
Today Vaxcyte has the market capitalization of 9.41B
When is the next Vaxcyte earnings date?▼
Vaxcyte is going to release the next earnings report on November 09, 2026.
What were Vaxcyte earnings last quarter?▼
PCVX earnings for the last quarter are -1.97 USD per share, whereas the estimation was -2.06 USD resulting in a +4.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaxcyte revenue for the last year?▼
Vaxcyte revenue for the last year amounts to 0 USD.
What is Vaxcyte net income for the last year?▼
PCVX net income for the last year is -766.63M USD.
How many employees does Vaxcyte have?▼
As of August 19, 2026, the company has 507 employees.
In which sector is Vaxcyte located?▼
Vaxcyte operates in the Health & Wellness sector.
When did Vaxcyte complete a stock split?▼
Vaxcyte has not had any recent stock splits.
Where is Vaxcyte headquartered?▼
Vaxcyte is headquartered in SAN CARLOS, United States.